Arima Genomics Announces New Study Showing Aventa™ Lymphoma Test Resolves Diagnostic Ambiguity and Guides Care in B-Cell Lymphoma Cases
Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment
Excerpt from the Press Release:
CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing that the Aventa Lymphoma test turns ambiguous FISH (fluorescent in situ hybridization) results into clear clinical answers for patients with diffuse large B-cell lymphoma (DLBCL).
Sensitive and precise testing for gene fusions and rearrangements is essential to assure an accurate lymphoma diagnosis. FISH is a widely used, probe-based test that relies on microscopy and interrogates only a single preselected target at a time, whereas Aventa Lymphoma leverages genome-wide Hi-C sequencing to assess all relevant fusions and rearrangements simultaneously in a single assay.
The new study, published in a special issue of the peer-reviewed scientific journal Genes entitled “Cytogenetics and Cytogenomics in Clinical Diagnostics: Innovations and Applications”, focused on a series of diagnostically challenging cases with atypical FISH findings.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?